Catalent signs agreement with Trizell, Thermo Fisher Scientific partners with JW Therapeutics and Aruvant chooses Lonza to manufacture a sickle cell gene therapy. Lovely to have you here for BioProcess Insider’s CGT services round-up. First up in our cell and gene therapy (CGT) services round-up is Catalent, which recently confirmed an agreement with Trizell to support the manufacturing of Trizell’s Phase I therapy to treat micro and macroangiopathies. The firm’s therapeutic is an advanced therapy medicinal product (ATMP) which uses…

Gilead has partnered with Gritstone to develop an HIV-specific therapeutic vaccine in a deal worth up to $725 million.  Gilead will pay $60 million when the deal closes, but could pay Gritstone up to $725 million if the option is exercised and commercial, clinical and regulatory milestones are achieved.   “Gilead and Gritstone are partnering together to test the ability of Gritstone’s vaccine platform to stimulate T cell (immune) responses against HIV,” a spokesperson for Gilead told BioProcess Insider. “This approach may have the…